Table 3.
Baselinea | Follow-upb |
18-24 months | |||||
---|---|---|---|---|---|---|---|
3 weeks | 3 months | 6 months | 9 months | 12 months | |||
Survey | |||||||
Demographics | + | ||||||
Diet (3-day diet record) | + | + | |||||
Health history | + | + | + | ||||
Health-related quality of life | + | + | + | ||||
Water survey | + | + | + | + | |||
Clinical | |||||||
Height (cm) | + | ||||||
Weight (Kg) | + | +c | + | ||||
Waist circumference (cm) | + | +c | + | ||||
Blood pressure (mm Hg) | + | +c | + | ||||
Medications | + | +c | + | ||||
Blood | |||||||
Blood sample | + | + | + | + | + | + | |
Serum creatinine (μmol/L) | + | + | + | + | + | + | +d |
Serum sodium (mmol/L) | + | + | + | + | + | + | |
Urea (mmol/L) | + | + | + | ||||
Osmolality (mOsm/kg) | + | + | + | ||||
Copeptin (pmol/L) | + | +c | |||||
Hematocrit (L/L) | + | + | + | ||||
Cystatin C (mg/L) | + | +c | |||||
HbA1c (%) | + | + | + | ||||
Plasma samples for long-term storage | + | ||||||
Urine | |||||||
24-hour urine sample (L) | + | + | + | +d | |||
Urine creatinine (mmol/d) | + | + | + | +d | |||
Urine sodium (mmol/d) | + | + | + | ||||
Urine potassium (mmol/d) | + | + | + | ||||
Urea (mmol/d) | + | + | + | ||||
Osmolality (mOsm/kg) | + | + | + | ||||
Albumin (mg/d) | + | + | + | ||||
Measured Creatinine clearance (mL/min/1.73 m2) | + | + | + | +d | |||
Random spot urine sample | + | ||||||
Specific gravity (g) | + | ||||||
Osmolality (mOsm/kg) | + |
Prerandomization.
Time after randomization.
While local labs are able to measure and process blood and urine samples, they do not measure weight, blood pressure, cystatin C, or copeptin; these measures will be obtained at the participants’ follow-up kidney care clinic visit (approximately 9 months after randomization).
Posttrial data (18-24 months after randomization) will be obtained from participants’ medical charts where possible to reduce respondent burden.
The “+” symbol indicates that the measure was collected at this time point.